Abstract
Background Francisella tularensis is a Gram-negative coccobacillus that causes the febrile illness tularemia. Subspecies that are pathogenic for humans include those comprising the type A (subspecies tularensis) or type B (subspecies holarctica) biovars. An attenuated live vaccine strain (LVS) developed from a type B isolate has previously been used to vaccinate at-risk individuals, but offers limited protection against high dose (>1000 CFUs) challenge with type A strains delivered by the respiratory route. Due to differences between type A and type B F. tularensis strains at the genetic level, it has been speculated that utilization of an attenuated type A strain as a live vaccine might offer better protection against homologous respiratory challenge compared with LVS. Here, we report the construction and characterization of an unmarked ΔpurMCD mutant in the highly virulent type A strain Schu S4.Methodology/Principal FindingsGrowth of Schu S4 ΔpurMCD was severely attenuated in primary human peripheral blood monocyte-derived macrophages and in the A549 human lung epithelial cell line. The Schu S4 ΔpurMCD mutant was also highly attenuated in mice when delivered via either the intranasal or intradermal infection route. Mice vaccinated intranasally with Schu S4 ΔpurMCD were well protected against high dose intradermal challenge with virulent type A or type B strains of F. tularensis. However, intranasal vaccination with Schu S4 ΔpurMCD induced tissue damage in the lungs, and conferred only limited protection against high dose Schu S4 challenge delivered by the same route. The level of protection observed was similar to that conferred following vaccination with wild-type LVS or the analogous LVS ΔpurMCD mutant.Conclusions/SignificanceCollectively, these results argue that development of the next generation live attenuated vaccine for Francisella should be based on use of the less pathogenic type B biovar rather than the more reactogenic type A biovar.
Highlights
Francisella tularensis is one of the most infectious bacterial species known, and is the etiological agent of the debilitating febrile illness tularemia
We recently reported that a marked deletion in an operon essential for purine biosynthesis in F. tularensis live vaccine strain (LVS) resulted in a strain that was highly attenuated for virulence in murine macrophages and in mice when delivered by the intraperitoneal (i.p.) route of infection [16]
To alleviate concerns associated with the use of antibiotic resistance genes in type A F. tularensis, deletion of purMCD was performed in both LVS and Schu S4 without the incorporation of an antibiotic resistance marker
Summary
Francisella tularensis is one of the most infectious bacterial species known, and is the etiological agent of the debilitating febrile illness tularemia. F. tularensis is comprised of four subspecies, of which subspecies tularensis (type A) and subspecies holarctica (type B) are the biovars most commonly associated with disease in humans. Subspecies that are pathogenic for humans include those comprising the type A (subspecies tularensis) or type B (subspecies holarctica) biovars. An attenuated live vaccine strain (LVS) developed from a type B isolate has previously been used to vaccinate at-risk individuals, but offers limited protection against high dose Due to differences between type A and type B F. tularensis strains at the genetic level, it has been speculated that utilization of an attenuated type A strain as a live vaccine might offer better protection against homologous respiratory challenge compared with LVS. We report the construction and characterization of an unmarked DpurMCD mutant in the highly virulent type A strain Schu S4
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call